

Curriculum vitae og publikationsliste for Jens Peter Gøtze

Født i Helsingør den 11. januar 1969. Gift, to børn.

Uddannelse og akademiske grader

1987: Studentereksamen fra Holte Gymnasium.
 1997: Medicinsk kandidat fra Københavns Universitet.
 2005: Medicinsk doktorgrad ved Københavns Universitet (ISBN 87-990801-0-9).
 2008: Speciallæge i klinisk biokemi.
 2012: Adjungeret professor i kardiovaskulær endokrinologi ved Aarhus Universitet.

Ansættelser

1993 til 1995: Skolarstipendiat, Kræftens bekæmpelse.
 1997 til 1998: Turnusansættelse, H:S Hvidovre Hospital.
 1998 til 1999: Introduktionsstilling, klinisk biokemisk afdeling, H:S Rigshospitalet.
 1999 til 2000: Introduktionsstilling, medicinsk afdeling B, H:S Rigshospitalet.
 2000 til 2003: Klinisk assistent, H:S Rigshospitalet.
 2003 til 2005: Undervisningsstilling, klinisk biokemisk afdeling, H:S Rigshospitalet.
 2005 til 2006: 1. reservelæge, klinisk biokemisk afdeling, H:S Rigshospitalet.
 2006 til 2007: 1. reservelæge, klinisk biokemisk afdeling, UMAS, Malmø.
 2007 til 2007: 1. reservelæge, klinisk biokemisk afdeling, Rigshospitalet, Region H.
 2007 til 2008: 1. reservelæge, klinisk biokemisk afdeling, Bispebjerg Hospital, Region H.
 2007-: Ekstern lektor ved det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
 2007 til 2009: Afdelingslæge, klinisk biokemisk afdeling, Rigshospitalet, Region H.
 2009-: Overlæge, klinisk biokemisk afdeling, Rigshospitalet, Region H.
 2013-: Forskningsansvarlig konsulent ved professionshøjskolen Metropol.

Forskningsproduktion

December 2014: I alt 203 publikationer bestående af 124 originalarbejder, 39 oversigtsartikler og letters, 11 editorials, 7 bogkapitler og 22 andre publikationer. Samlet antal citationer 2044; gennemsnitlig citation 10.9; H-indeks (Web of Science) = 22.

Ledelse og administration

Fra 2009 ansvarlig for klinisk biokemisk afdelings koagulationslaboratorium. Laboratoriet betjener Østdanmark med højt specialiserede analyser for hæmofili sygdomme samt på regionsniveau for trombose relaterede sygdomme, herunder genetisk udredning for sjældne, arvelige trombose sygdomme. Funktionen forudsætter tæt samarbejde med en klinisk enhed på Rigshospitalet for samme. Fra 2011 desuden økonomisk ansvarlig for afdelingens peptid forskningssektion, som består af tre professorer, en overlæge, post-docs, ph.d.-studerende, speciale studerende og bioanalytikere. Lederuddannelse via Region H (1 årigt kursus). Indstillet af sektionens ansatte til Region Hovedstadens lederpris 2013.

Undervisning og pædagogik

- Underviser i makroskopisk anatomi for læge- og tandlægestuderende ved Københavns Universitet (1994-1996).
- Anatomiunderviser ved optræningscentret i Karlslunde (1999-).
- Undervisning af medicinstuderende (1999-) og A-kursister i klinisk biokemi (2006-).
- Prægraduat undervisning af medicinstuderende ved Københavns Universitet for klinisk biokemisk afdelings professorer (2009-) med emner i klinisk endokrinologi samt trombose og hæmostase.

- Underviser ved ph.d.-kurser i kardiologi og klinisk biokemi ved henholdsvis Aarhus og Københavns Universitet (2009-).
- Voksenpædagogisk kursus (1 uge).
- Hovedansvarlig for årligt ph.d.-kursus ved Københavns Universitet i videnskabelig præsentation (2012-).

Videnskabelig vejleder

Aktuelt vejleder for en ph.d. studerende, fire post-doc's, fire kommende ph.d. studerende og to læger i uddannelse.

- Vejleder for ph.d.-stud. Bjarke Follin Larsen (2013-). Projektet omhandler behandling med stamceller i klinisk kardiologi.
- Supervisor for ph.d. Ewa Soltysinska som post-doc.
- Supervisor for ph.d. Nora Zois som post-doc.
- Supervisor for ph.d. Julie Smith som post-doc.
- Supervisor for ph.d. Jakob Albrethsen som post-doc.
- Vejleder for cand. scient. Annette Timm.
- Vejleder for cand. scient. Dijana Terzic og kommende ph.d..
- Vejleder for cand. scient. Lasse Holst Hansen og kommende ph.d..
- Vejleder for cand. scient. Christina Kjær og kommende ph.d..
- Vejleder for læge, ph.d., David Sonne under uddannelse.
- Vejleder for læge Jana Dravecka under uddannelse.

Tidligere vejleder for ph.d.-afhandlinger og kandidatopgaver ved det Sundhedsvidenskabelige Fakultet i København og ved Aarhus Universitet:

- Projektvejleder for Søren Junge Nielsen (afhandling forsvaret 2008). Projektet omhandlede C-type natriuretisk peptid, metodeudvikling, karakterisering af vævsekspression, samt proCNP som biomarkør ved prostatakræft.
- Projektvejleder for Maren Skau (afhandling forsvaret 2010). Projektet omhandlede natriuretiske peptider i cerebrospinalvæske ved idiopatisk, forhøjet intrakranielt tryk
- Projektvejleder for Birgitte Kousholt (afhandling forsvaret 2012). Projektet omhandlede natriuretiske peptider i kardioprotektion. Et originalt arbejde publiceret og to manuskripter indsendt til tidsskrifter.
- Hovedvejleder for Julie Smith (afhandling forsvaret 2012). Projektet omhandlede natriuretiske peptider i neonatologi og medfødt hjertesygdom.
- Projektvejleder for ph.d.-stud. Ingrid Hunter (afhandling forsvaret 2013). Projektet omhandlede natriuretiske peptider i forsøgsdyr og ved hjertesygdom.
- Hovedvejleder for Solvej Lippert (ph.d. afhandling forsvaret 2014). Projektet omhandlede C-type natriuretisk peptid i urogenital sygdom, herunder prostatakræft.
- Hovedvejleder for Annette Timm (kandidatopgave forsvaret 2013). Projektet omhandlede nye diagnostiske muligheder ved von Willebrands sygdom.
- Hovedvejleder for Lasse Holst Hansen (kandidatopgave forsvaret 2014). Projektet omhandlede glykosylering i hjertet med fokus på natriuretiske hormoner.

Tidligere vejleder for 4 skolarstipendiater:

- Stud.med. Anders Hejmdal Poulsen (natriuretiske peptider og kardiogent shock).
- Stud.med. Jesper Madsen (natriuretiske peptider og post-translational processing).
- Stud.med. Louise Honoré (oprensning af humant N-terminalt proBNP).
- Stud.med. Signe Eiland (gastrin i ventrikelkræft).

Tidligere vejleder for årsstuderende, stud.med. Martin Frydland, (kromogranin A ved akut myokardieinfarkt). Hovedvejleder for Lasse Holst Hansen (kandidatprojekt i molekylær biomedicin) 2012-14.

Desuden vejleder for otte OSVAL 2 opgaver (stud.med. Anders Hejmdal Poulsen, stud.med. Jesper Madsen, stud.med. Louise Honoré, stud.med. Casper Bang, stud.med. Martin Andersen, stud.med. Camilla Bardram Johnbeck, stud.med. Ida Willer, stud.med. Kristina Pilgaard Lærum). Daglig supervisor for to forskningslaboranter samt bioanalytikere i rutinefunktioner.

Priser

- Vinder af foredragskonkurrence for yngre kardiologer i Norden (XIX Nordic Congress of Cardiology, Odense 2003; *Ugeskr Laeger* 2003;**165**:2923), samt 2. plads i Astrup konkurrencen (Nordisk Kongres i Klinisk Kemi, Malmø 2004; *Klinisk Kemi i Norden* 2004;**16**:8-12).
- Tildelt Christenson-Cesons legat (2006).
- Tildelt Jacobinermedaljen af Selskabet for Teoretisk og Anvendt Medicin (2008).
- Tildelt Odd Fellow Ordenens Forskerpris (2014).

Videnskabelig bedømmer

- Bedømmer på Sundhedsvidenskabelig ph.d.-afhandling ved Københavns Universitet (cand.med. Tue Christoffersen, 23. marts 2007).
- Opponent på sundhedsvidenskabelig doktorafhandling ved Lunds Universitet (Cecilia Oslakovic, juni 2010).
- Bedømmer på lektorat ved medicinsk forskningslaboratorium, Institut for Klinisk Medicin, Health, Aarhus Universitet (Juni 2012).
- Bedømmer på forskningsprofessorat ved Medical School, University of Otago, Christchurch, New Zealand (august 2012).
- Bedømmer på sundhedsvidenskabelig ph.d. afhandling ved Syddansk Universitet (cand.scient.pharm Helene Skjøt-Arkil, April 2013).
- Bedømmer på sundhedsvidenskabelig doktordisputats ved Oslos Universitet, Norge (cand. med. Erik Tandberg Askevold, Juli 2013).
- Bedømmer på ph.d. afhandling ved University of Otago, New Zealand (Mauthri J Siriwardena, august 2013).
- Reviewer (n = 107) på manuskripter for internationale tidsskrifter inkl. *European Heart Journal*, *American Journal of Physiology*, *Clinical Chemistry*, *FASEB Journal*, *Journal of the American College of Cardiology*, *Circulation*, og *Circulation Research*.

Editor-funktioner, arrangerede møder

- Arrangør af seminar om natriuretiske peptider (København 2002) og Klinisk Biokemisk Årsmøde (København 2003). Medredaktør for Dansk Selskab for Klinisk Biokemi medlemsblad (2005-2007).
- Initiativtager til og arrangør af "Båstad" seminaret om kardiovaskulær endokrinologi (2009-).
- Initiativtager til og arrangør af "The Abildgaard Symposium 2010: Mammalian Cardiovascular Endocrinology". Et samarbejde mellem Rigshospitalet og KU-LIFE, København.
- Chair for "The 19th International Symposium on Regulatory Peptides, Copenhagen, 2012.
- Medlem af *Nordic Hemophilia Council*, NCG (2008-).
- Medlem af Editorial Board for *Biomarkers in Medicine* (2009-).
- Medlem af Editorial Board for *Journal of Pediatric Biochemistry* (2009-).
- Medlem af Editorial Board for *Journal of Geriatric Cardiology* (2010-).
- Medlem af Editorial Board for *Journal of Biomarkers* (2012-).
- Medlem af Editorial Board for *Research Journal of Endocrinology and Metabolism* (2013-).
- Medlem af Editorial Board for *Regulatory Peptides* (2014-).
- Associate Editor for *Cardiovascular Endocrinology* (2012-).

Faglige aktiviteter

- Tillidsrepræsentant i 2½ år for yngre læger på Rigshospitalet. Gennemført uddannelsen som tillidsrepræsentant (FAYL kursus I+II).

- Udpeget af Dansk Selskab for Klinisk Biokemi og uddannet af Sundhedsstyrelsen til inspektor for de diagnostiske specialer (maj 2010).

Kurser

Deltaget i eksterne kurser om kardiologiske emner samt A-kurser under hoveduddannelsen i klinisk biokemi. Bestået FELASA C-kursus = selvstændig tilladelse til dyreforsøg.

Eksterne bevillinger de sidste 3 år

2008:	200.000 kr. fra Lundbeckfonden.
2009:	500.000 kr. fra Lundbeckfonden.
2009:	150.000 kr. fra P.A. Messerschmidtfonden.
2009:	125.000 kr. fra Eva og Henry Frænkels Mindefond.
2010-2012:	Rammebevilling fra Rigshospitalets forskningsråd (3 x 300.000 kr.).
2010:	750.000 kr. fra Lundbeckfonden.
2012:	Rammebevilling fra Novo Nordisk fonden (5 x 1.000.000 kr.).
2013:	30.000 kr. fra Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond.
2013:	1.463.000 kr. fra Region Hovedstaden.
2014:	100.000 kr. fra Arvid Nilssons Fond.
2014:	200.000 kr. fra Toyota-Fonden.

Videnskabeligt samarbejde

- På nationalt plan samarbejde med forskningsledere i egen afdeling (professor Lars Bo Nielsen og professor Jens F. Rehfeld) samt på Rigshospitalet (professorer Lars Køber, Jens Kastrup og Jesper Hastrup Svendsen, samt overlæge Finn Gustafsson). Desuden samarbejde med professor Jan Skov Jensen (Gentofte Hospital), professor Søren Møller (Hvidovre Hospital), professor Jørgen Jeppesen (Glostrup Hospital), professor Michael Hasenkam (Skejby Hospital), professor Lisbeth Højer Olsen (KU-LIFE) og professor Jan Fahrenkrug (Bispebjerg Hospital).
- Internationale samarbejder med professor Ulf Dahlström (Linköbing Universitet, Sverige), professor John Burnett Jr. (Mayo klinikken, USA), professor Fred Apple (Minnesota University, USA), professor Gary Baxter (Cardiff University, UK), professor Leo Dunkel (Oulu University, Finland) og professor Mark Richards (Otago University, New Zealand).

Forskningsvision

Min vision er konsolidering af *kardiovaskulær endokrinologi* som en tværfaglig disciplin med udgangspunkt i innovative biokemiske og molekylærbiologiske metoder for relevante peptidsystemer. Arbejdet baseres på solid biokemisk metodologi, relevante eksperimentelle modeller for human hjertesygdom, samt afprøvning i store kliniske studier. Emnet er per definition tværfagligt og kræver et tæt samarbejde med basalforskere og klinikere. Helt overordnet er målet at kunne bidrage til ny erkendelse af endokrine organsammenhænge ved human hjertesygdom og dermed mulighed for nye diagnostiske og terapeutiske tiltag.

Publikationsliste

I. Originalarbejder (123).....	6
II. Oversigtsartikler & letters (39).....	15
III. Editorials (11)	18
IV. Bogkapitler (7).....	19
V. Andre publikationer (15).....	20
VI. Indlæg (7).....	21
VII. Patentansøgninger (2).....	22
VIII. Manuskripter indsendt til tidsskrift.....	23

Det totale antal publikationer er 202. Tallene i parentes angiver antal publikationer pr. kategori. Abstracts er ikke inkluderet.

I. Originalarbejder (123)

1. **Gøtze JP**, Lindeskog P, Törnquist CSI. Effects of induction and age-dependent enzyme expression on lung bioavailability, metabolism, and DNA binding of urban air particulate-absorbed benzo[a]pyrene, 2-nitrofluorene, and 3-amino-1,4-dimethyl-5H-pyridol-(4,3)-indole. *Environ Health Perspect* 1994;**102** Suppl 4:147-156.
2. **Gøtze JP**, Rehfeld JF. Displaced chromatographic elution of gastrin-17 in normal human serum. *Scand J Clin Lab Invest* 1994;**54**:673-676.
3. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. Excretion of progastrin products in human urine. *Am J Physiol* 1999;**276**:G985-G992.
4. **Gøtze JP**, Jensen CH. Follow-up of volar plate interposition arthroplasty (Tupper) of the metacarpophalangeal joints in rheumatoid hands: Preliminary findings. *Scand J Plast Reconstr Surg Hand Surg* 2000;**34**:249-251.
5. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. The metabolism of gastrin-52 and gastrin-6 in pigs. *Am J Physiol Gastroentest Liver Physiol* 2000;**279**:G552-560.
6. **Gøtze JP**, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma – coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. *Cancer* 2000;**88**:2487-2494.
7. **Gøtze JP**, Thorsen S, Haunsø S. Erhvervet warfarinresistens hos en patient med mekanisk mitralklap. *Ugeskr Laeger* 2001;**163**:7075-7076.
8. **Gøtze JP**, Kastrup J, Pedersen F, Rehfeld JF. Quantification of Pro-B-Type Natriuretic Peptide and its products in Human plasma by use of an analysis independent of precursor processing. *Clin Chem* 2002;**48**:1035-1042.
9. Christoffersen C, **Gøtze JP**, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, Nielsen LB. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. *Hypertension* 2002;**40**:54-60.
10. Konturek PC, Bielanski W, Konturek SJ, Hartwich A, Pierzhalski P, Duda A, Karczewska E, Marlicz M, Starzynska T, Lawniczak M, Darasz Z, **Gøtze JP**, Rehfeld JF, Hahn EG. Progastrin and cyclooxygenase-2 in colorectal cancer. *Dig Dis Sci* 2002;**47**:1984-1991.
11. **Gøtze JP**, Rehfeld JF. Impact of assay epitope specificity in gastrinoma diagnosis. *Clin Chem* 2003;**49**:333-334.
12. **Gøtze JP**, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP gene expression associated with myocardial ischemia. *FASEB J* 2003;**17**:1105-1107. Epub 2003 Apr 22 (10.1096/fj.02-0796fje).
13. Konturek SJ, Gonciarz M, Gonciarz Z, Bielanski W, Mazur W, Mularczyk A, Konturek PC, **Gøtze JP**, Rehfeld JF. Progastrin and its products from patients with chronic viral hepatitis and liver cirrhosis. *Scand J Gastroenterol*, 2003;**38**:643-647.
14. Christoffersen C, Bollano E, Lindegaard MLS, Bartels ED, **Gøtze JP**, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. *Endocrinology* 2003;**144**:3483-3490.
15. Henriksen JH, **Gøtze JP**, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in

patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. *Gut* 2003;**52**:1511-1517.

16. Konturek SJ, Konturek PC, Bielanski W, Karczewska E, Zuchowicz M, Hartwich A, Rehfeld JF, **Gøtze JP**, Hahn EG. Serum progastrin and its products, gastric acid secretion and serum pepsinogen I in gastric cancer. *Digestion* 2003;**68**:169-177.
17. **Gøtze JP**, Henriksen JH, Fuglsang S, Christensen E, Bendtsen F, Møller S. Cirrotisk kardiomyopati: øget cirkulerende pro-brain-natriuretisk peptid og brain-natriuretisk peptid ved cirrose. *Ugeskr Laeger* 2004;**166**:2999-3002 (parallellpublikation).
18. **Gøtze JP**, Videbæk R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. *J Heart Lung Transplant* 2004;**23**:80-87.
19. **Gøtze JP**, Wang Y, Rehfeld JF, Jørgensen E, Kastrup J. Coronary angiography transiently increases plasma pro-B-type natriuretic peptide. *Eur Heart J* 2004;**25**:759-764.
20. **Gøtze JP**, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. *FASEB J* 2004;**18**:1928-1930. Epub 2004 Sept 22 (10.1096/fj.03-1336fje).
21. **Gøtze JP**, Rehfeld JF, Videbæk R, Friis-Hansen L, Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. *Eur J Heart Fail* 2005;**7**:69-74.
22. Wang YZ, **Gøtze JP**, Videbæk R, Rehfeld JF, Kastrup J. Increased circulating endothelins are not of cardiopulmonary origin in heart failure patients. *Scand J Clin Lab Invest* 2005;**65**:341-347.
23. **Gøtze JP**, Paloheimo LI, Linnala A, Sipponen P, Hansen CP, Rehfeld JF. Gastrin-17 specific antibodies are too specific for gastrinoma diagnosis but stain G-cells. *Scand J Gastroenterol* 2005;**40**:596-598.
24. Halse KG, Lindegaard MLS, **Gøtze JP**, Damm P, Mathiesen ER, Nielsen LB. Increased plasma pro-B-type natriuretic peptide in infants of women with type I diabetes. *Clin Chem* 2005;**51**:2296-2302.
25. Nielsen SJ, Rehfeld JF, Pedersen F, Kastrup J, Videbæk R, **Gøtze JP**. Measurement of pro-C-type natriuretic peptide in plasma. *Clin Chem* 2005;**51**:2173-2176.
26. **Gøtze JP**, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal pro-BNP are both extracted in the normal kidney. *Eur J Clin Invest* 2006;**36**:8-15.
27. **Gøtze JP**, Hansen CP, Rehfeld JF. Antral content, secretion and peripheral metabolism of N-terminal progastrin fragments. *Regul Pept* 2006;**133**:47-53.
28. **Gøtze JP**, Rehfeld JF, Carlsen J, Videbæk R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: A new plasma marker of cardiopulmonary disease. *Regul Pept* 2006;**133**:134-138.
29. Runge M, Hughes P, **Gøtze JP**, Petersen R, Steinbrüchel DA. Evaluation of myocardial metabolism with microdialysis after protection with cold blood- or crystalloid cardioplegia. A porcine model. *Scand Cardiovasc J* 2006;**40**:186-193.
30. **Gøtze JP**, Møgelvang R, Måge L, Scharling H, Schnohr P, Søgaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. *Eur Heart J* 2006;**27**:3004-3010.

31. Hejmdal A, Boesgaard S, Lindholm MG, **Gøtze JP**. B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. *J Card Fail* 2007;**13**:184-188.
32. Nybo M, Nielsen LB, Nielsen SJ, Lindegaard MLS, Damm P, Rehfeld JF, **Gøtze JP**. Discordant expression of pro-B-type and pro-C-type natriuretic peptide in newborn infants of mothers with type 1 diabetes. *Regul Pept* 2007;**141**:135-139.
33. Damgaard M, **Gøtze JP**, Norsk P, Gadsbøll N. Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy subjects and patients with compensated heart failure. *Eur Heart J* 2007;**28**:2726-2731.
34. Ripa RS, Wang Y, **Gøtze JP**, Jørgensen E, Johnsen HE, Kastrup J. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease — Indicators of myocardial ischemic burden? *Int J Cardiol* 2007;**120**:181-187.
35. Alehagen U, **Gøtze JP**, Dahlström U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. *Clin Chim Acta* 2007;**382**:8-14.
36. Nybo M, Benn M, Møgelvang R, Jensen JS, Schnohr P, Rehfeld JF, **Gøtze JP**. Impact of hemoglobin on plasma pro-B-type natriuretic peptide concentrations in the general population. *Clin Chem* 2007;**53**:1921-1927.
37. Møgelvang R, **Gøtze JP**, Schnohr P, Lange P, Sogaard P, Rehfeld JF, Jensen JS. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. *J Am Coll Cardiol* 2007;**50**:1694-1701.
38. Nielsen SJ, Rehfeld JF, **Gøtze JP**. Mismeasure of C-type natriuretic peptide. *Clin Chem* 2008;**54**:225-227.
39. Nielsen SJ, **Gøtze JP**, Jensen H, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. *Regul Pept* 2008;**146**:204-212.
40. Møller CH, Nørgaard MA, **Gøtze JP**, Andersen CB, Olsen VN, Steinbrüchel DA. Selective retrograde venous revascularization of the myocardium when PCI or CABG is impossible: investigation in a porcine model. *Heart Surg Forum* 2008;**11**:E99-104.
41. Friis-Hansen L, Sælsen L, Abildstrøm SZ, **Gøtze JP**, Hilsted LM. An algorithm for applying flagged Sysmex XE-2100 absolute neutrophil counts in clinical practice. *Eur J Haematol* 2008;**81**:140-153.
42. **Gøtze JP**, Dahlström U, Rehfeld JF, Alehagen U. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. *Clin Chem* 2008;**54**:1780-1787.
43. Christiansen MS, Iversen K, Larsen CT, **Gøtze JP**, Hommel E, Mølviig J, Pedersen BK, Magid E, Feldt-Rasmussen B. Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. *Scand J Clin Lab Invest* 2009;**69**:272-281.
44. Poulsen TD, Andersen LW, Steinbrüchel D, **Gøtze JP**, Jørgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. *J Cardiothorac Vasc Anesth* 2009;**23**:316-323.
45. Nielsen SJ, Iversen P, Jensen H, Rehfeld JF, **Gøtze JP**. C-type natriuretic peptide in prostate cancer. *APMIS* 2009;**117**:60-67.

46. Møgelvang R, Søgaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, **Gøtze JP**, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. *Circulation* 2009;**119**:2679-2685.
47. Møgelvang R, **Gøtze JP**, Pedersen SA, Olsen NT, Marrot JL, Schnohr P, Søgaard P, Jensen JS. Preclinical systolic and diastolic dysfunction assessed by tissue doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. *J Card Fail* 2009;**15**:489-495.
48. Schou M, Alehagen U, **Gøtze JP**, Gustafsson F, Dahlström U. Effect of estimated glomerular filtration rate on plasma concentrations of B-type natriuretic peptides measured with multiple immunoassays in elderly individuals. *Heart* 2009;**95**:1514-1519.
49. Nilsson B, **Gøtze JP**, Chen X, Pehrson S, Svendsen JH. Increased NT-pro-B-type natriuretic peptide independently predicts outcome following catheter ablation of atrial fibrillation. *Scand J Clin Lab Invest* 2009;**69**:843-850.
50. Pecini R, Hammer-Jensen S, Dalsgaard M, **Gøtze JP**, Hassager C, Køber L. Determinants of exercise-induced increase of mitral regurgitation in patients with acute coronary syndromes. *Echocardiography* 2010;**27**:567-574.
51. **Gøtze JP**, Georg B, Jørgensen HL, Fahrenkrug J. Chamber-dependent circadian expression of cardiac natriuretic peptides. *Regul Pept* 2010;**160**:140-145.
52. Skau M, **Gøtze JP**, Rehfeld JF, Jensen R. Natriuretic pro-peptides in idiopathic intracranial hypertension. *Regul Pept* 2010;**164**:71-77.
53. Bonfils PK, Damgaard M, Taskiran M, **Gøtze JP**, Norsk P, Gadsbøll N. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. *Eur J Heart Fail* 2010;**12**:995-1001.
54. Bartels EM, Nielsen JM, Bisgaard LS, **Gøtze JP**, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. *Endocrinology* 2010;**151**:5218-5225.
55. Lippert SK, Rehfeld JF, **Gøtze JP**. Processing-independent analysis for pro-C-type natriuretic peptide. *J Immunol Methods* 2010;**362**:32-37.
56. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. *Clin Chem* 2010;**56**:1718-1724.
57. Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, **Gøtze JP**, Johansen JS, Kastrup J, The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. *Inflamm Res* 2011;**60**:281-287.
58. Harutjunjan MJ, Mathiasen AB, Winkel P, **Gøtze JP**, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjølner E, Kolmos, HJ, Gluud C, Kastrup J, CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. *Scand J Clin Lab Invest* 2011;**71**:52-62.
59. Hermann TS, Dall CH, Christensen SB, **Gøtze JP**, Prescott E, Gustafsson F. Effect of high intensity exercise on peak oxygen uptake and endothelial function in long-term heart transplant recipients. *Am J Transplant* 2011;**11**:536-541.

60. Olsen NT, Sogaard P, Larsson HBW, **Gøtze JP**, Jons C, Mogelvang R, Nielsen OW, Fritz-Hansen T. Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitation during conservative management and after surgery. *JACC Cardiovasc Imaging* 2011;**4**:223-230.
61. Passino C, Franzino E, Giannoni A, Prontera C, **Gøtze JP**, Emdin M, Clerico A. B-type natriuretic peptide secretion following scuba diving. *Biomarkers Med* 2011;**5**:205-209.
62. Sennels HP, Jørgensen HL, Hansen AL, **Gøtze JP**, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: The Bispebjerg study of diurnal variations. *Scand J Clin Lab Invest* 2011;**71**:532-541.
63. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, **Gøtze JP**, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. *Gastroenterology* 2011;**140**:1444-1453.
64. Hunter I, Alehagen U, Dahlström U, Rehfeld JF, Crimmins DL, **Gøtze JP**. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. *Clin Chem* 2011;**57**:1327-1330.
65. Hunter I, Rehfeld JF, **Gøtze JP**. Measurement of the total proANP product in mammals by processing independent analysis. *J Immunol Methods* 2011;**370**:104-110.
66. Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, **Gøtze JP**, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. *Scand J Clin Lab Invest* 2011;**71**:439-447.
67. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Association of copeptin and N-terminal proBNP concentrations to risk of cardiovascular death in elderly patients with symptoms of heart failure. *JAMA* 2011;**305**:2088-2095.
68. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
69. Sennels HP, Jørgensen HL, **Gøtze JP**, Fahrenkrug J. Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males – The Bispebjerg study of diurnal variations. *Scand J Clin Lab invest* 2012;**72**:287-295.
70. Husby S, Lind B, **Gøtze JP**. Practical use of natriuretic peptide measurement: questionnaire results from general practitioners and cardiologists. *Biomark Med* 2012;**6**:13-18.
71. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
72. Smith J, **Gøtze JP**, Sondergaard L, Kjaergaard J, Iversen KK, Vejlstrop NG, Hassager C, Andersen CB. Myocardial hypertrophy after pulmonary regurgitation and valve implantation in pigs. *Int J Cardiol* 2012;**159**:29-33.
73. Kilpeläinen L, Ivaska KK, Kuiri-Hänninen T, Väänänen HK, Rehfeld JF, **Gøtze JP**, Sankilampi U, Dunkel L. Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. *J Bone Miner Res* 2012;**27**:1528-1535.

74. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Hildebrandt P, Gustafsson F. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. *J Card Fail* 2012;**18**:351-358.
75. Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, **Gøtze JP**, Gustafsson I. Prediction of outcome by highly sensitive troponin-T in outpatients with chronic systolic left ventricular heart failure. *Am J Cardiol* 2012;**110**:552-557.
76. Munk M, Memon AA, **Gøtze JP**, Nielsen LB, Nexø E, Sørensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and in cultured cardiomyocytes. *PLoS One* 2012;**7**:e40243.
77. Kousholt BS, Larsen JKR, Bisgaard L, Burnett JC Jr, Hasenkam JM, **Gøtze JP**. Natriuretic peptide infusion reduces myocardial injury during acute ischemia/reperfusion. *Cardiovasc Endocrinol* 2012;**1**:4-12.
78. Terzic D, Johansson-Fällgren AS, Ragnarsson O, **Gøtze JP**, Hammarsten O. Evaluation of a sensitive copeptin assay for clinical measurement. *Open Clin Chem J* 2012;**5**:21-26.
79. Møller S, Mortensen C, Bendtsen F, Jensen LT, **Gøtze JP**, Madsen JL. Cardiac sympathetic imaging with *mIBG* in cirrhosis and portal hypertension: relation to autonomic and cardiac function. *Am J Physiol Gastrointest Liver Physiol* 2012;**303**:G1228-1235.
80. **Gøtze JP**, Jørgensen HL, Sennels HP, Fahrenkrug J. Diurnal plasma concentrations of natriuretic propeptides in healthy young males. *Clin Chem* 2012;**58**:789-792.
81. Alehagen U, Dahlström U, Carstensen J, Rehfeld JF, **Gøtze JP**. Combined measurement of copeptin, high-sensitivity troponin T, and N-terminal proBNP improves the identification of patients at risk of cardiovascular death. *Cardiovascular Endocrinology* 2012;**1**:68-73.
82. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. *J Card Fail* 2013;**19**:31-39.
83. Smith J, Halse KG, Damm P, Lindegaard MLS, Amer-Wählin I, Hertel S, Johansen M, Mathiesen ER, Nielsen LB, **Gøtze JP**. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. *Biomark Med* 2013;**7**:139-146.
84. Mygind ND, Iversen K, Køber L, **Gøtze JP**, Nielsen H, Boesgaard S, Bay M, Johansen J, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. *J Intern Med* 2013;**273**:205-216.
85. Iversen K, Køber L, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW. Troponin T is a strong marker of mortality in hospitalized patients. *Int J Cardiol* 2013;**168**:818-824.
86. Harutyunyan M, **Gøtze JP**, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjølner E, Kolmos HJ, Gluud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial. *Immunobiology* 2013;**218**:945-951.
87. **Gøtze JP**, Eiland S, Svendsen LB, Vainer B, Hannibal J, Rehfeld JF. Characterization of gastrins and their receptor in solid human gastric adenocarcinomas. *Scand J Gastroenterol* 2013;**48**:688-695.

88. Smith J, Christoffersen C, Nørgaard LM, Olsen LH, Vejstrup NG, Andersen CB, **Gøtze JP**. Cardiac natriuretic peptide gene expression and plasma concentrations during the first 72 hours of life in pigs. *Endocrinology* 2013;**154**:1864-1872.
89. **Gøtze JP**. Plasma proANP decreases after meal intake. *Clin Chem* 2013;**59**:1270-1271.
90. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtze JP**, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. *Hypertension* 2013; **62**:147-153.
91. Halse KG, Lindegaard LS, Amer-Wahlin I, Hertel S, Johansen M, Nielsen LB, **Gøtze JP**, Mathiesen ER, Damm P. Cardiac function in offspring of women with diabetes using fetal ECG, umbilical cord blood pro-BNP, and neonatal interventricular septal thickness. *Cardiovasc Endocrinol* 2013;**2**:55-59.
92. Lyngbæk S, Winkel P, **Gøtze JP**, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J, the CLARICOR Trial Group. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. *Eur J Prev Cardiol* 2013, in press.
93. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen VB, Gadsbøll N. The influence of high versus low sodium intake on blood pressure and haemodynamics in patients with morbid obesity. *J Hypertens* 2013;**31**:2220-2229.
94. Krogh J, **Gøtze JP**, Jørgensen MB, Kristensen LØ, Kistorp C, Nordentoft M. Copeptin during rest and exercise in major depression. *J Affect Disord* 2013;**151**:284-290.
95. Frydland M, Kousholt B, Larsen JR, Burnett JC Jr, Hilsted L, Hasenkam JM, **Gøtze JP**. Increased N-terminal CgA in circulation associated with cardiac reperfusion in pigs. *Biomark Med* 2013;**7**:959-967.
96. Cirera S, Moesgaard SG, Zois NE, Ravn N, **Gøtze JP**, Cremer SE, Teerlink T, Leifsson PS, Hønge JL, Hasenkam MJ, Olsen LH. Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model. *Endocr Connect* 2013;**2**:161-171.
97. Lauridsen BK, Iversen K, Hunter I, Bay M, Kirk V, Nielsen OW, Nielsen H, Boesgaard S, Køber L, **Gøtze JP**. ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. *BMJ Open* 2013;**3**:e003288.
98. Christensen HM, Schou M, **Gøtze JP**, Faber J, Frystyk J, Flyvbjerg A, Kistorp C. Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. *BMC Cardiovasc Disord* 2013;**13**:80.
99. Bosselmann H, Egstrup M, Rossing K, Gustafsson I, Gustafsson F, Tønder N, Kistorp CN, **Gøtze JP**, Schou M. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. *Int J Cardiol* 2013;**170**:202-207.
100. Wiese S, Mortensen C, **Gøtze JP**, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. *Liver Int* 2014;**34**:e19-30.
101. Rank UC, Hovinga JK, Taleghani MM, Lämmle B, **Gøtze JP**, Nielsen OJ. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the *ADAMTS13* gene. *Eur J Haematol* 2014;**92**:168-171.

102. Ruwald MH, **Gøtze JP**, Bech J, Nielsen OW, Madsen BK, Nielsen LB, Mouridsen M, Ruwald A-CH, Madsen JK, Pedersen S. NT-proBNP independently predicts long-term mortality in patients admitted for coronary angiography. *Angiology*, 2014;65:31-36.
103. Asferg C, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtze JP**, Jeppesen J. Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men. *Am J Hypertens* 2014;27:620-627.
104. Gustafsson G, Gude E, Sigurdardottir V, Aukrust P, Solbu D, **Gøtze JP**, Gullestad L. Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. *Biomark Med* 2014;8:239-245.
105. Rehfeld JF, Bardram L, Hilsted L, **Gøtze JP**. An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. *Biomark Med* 2014;8:571-580.
106. Hansen LH, Smith J, **Gøtze JP**. Cardiac C-type natriuretic peptide gene expression and plasma concentrations in neonatal piglets. *Regul Pept* 2014;188:66-69.
107. Skov J, Holst JJ, **Gøtze JP**, Frøkiær J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. *Endocr Connect* 2014;3:11-16.
108. Dalsgaard M, Iversen K, Kjaergaard J, Grande P, **Gøtze JP**, Clemmensen P, Hassager C. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis. A placebo-controlled, randomized study. *Am Heart J* 2014;167:226-234.
109. Kimer N, **Gøtze JP**, Bendtsen F, Møller S. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. *Eur J Clin Invest* 2014;44:441-452.
110. **Gøtze JP**, Hilsted L, Rehfeld JF, Alehagen U. Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. *Endocr Connect* 2014;3:47-56.
111. Asferg CL, Andersen UB, Linneberg A, **Gøtze JP**, Jeppesen JL. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. *Diabet Med* 2014;31:728-732.
112. Timm A, Fahrenkrug J, Jørgensen HL, Sennels HP, **Gøtze JP**. Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations. *Eur J Haematol* 2014, in press.
113. Iversen K, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber LV. Risk stratification in emergency patients by copeptin. *BMC Medicine* 2014;12:80 – in press.
114. Kjeld T, Jattu T, Nielsen HB, **Gøtze JP**, Secher NH, Olsen NV. Release of EPO, S100B and neuron-specific enolase after breath-hold in free divers. *Scand J Med Sci Sports*, in press.
115. Asferg CL, Andersen UB, Linneberg A, **Gøtze JP**, Jeppesen JL. Copeptin, a marker of the individual stress level, is associated with higher glucose and insulin levels but not higher blood pressure in obese men. *Diabetic Medicine*, in press.
116. Lindberg S, Jensen JS, Pedersen SH, Galatius S, **Gøtze JP**, Møgelvang R. ProANP independently predicts mortality and cardiovascular events in patients with STEMI. *Eur J Prev Cardiol*, in press.

117. Von Scholten BJI, Lajer M, **Gøtze JP**, Persson F, Rossing P. Time course of the antihypertensive effects of liraglutide treatment. *Diabetic Med*, in press.
118. Joergensen C, Tarnow L, **Gøtze JP**, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in type 1 diabetic patients with diabetic nephropathy – a randomized trial. *Diabetic Med*, in press.
119. Kistorp C, Bliddal H, **Gøtze JP**, Christensen R, Faber J. Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. *BMC Obesity*, in press.
120. Lippert SK, Iversen P, Brasso K, **Gøtze JP**. C-type natriuretic peptide and its precursor: Potential markers in human prostate cancer. *Biomarkers Med*, in press.
121. Andersen MJ, Ersbøll M, Bro-Jeppesen J, Møller JE, Hassager C, Køber L, Borlaug BA, **Gøtze JP**, Gustafsson F. Prediction of exercise hemodynamics after myocardial infarction using multiple biomarkers. *J Cardiac Failure*, in press.
122. Theilade S, Hansen TW, **Gøtze JP**, Rossing P. Increased Plasma concentrations of midregional pro-atrial natriuretic peptide in plasma is associated with risk of cardiorenal dysfunction in patients with type 1 diabetes. *Am J Hypertension*, in press.
123. Balling L, Gustafsson F, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber L, Iversen K. Hyponatremia at hospital admission is a predictor of overall mortality. *J Intern Med*, in press.
124. Holmager P, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Gustafsson F, Klausen TW, Faber J, Kistorp K. The influence of diabetes mellitus on mid-regional pro-adrenomedullin concentrations and prognostic value in heart failure patients. *J Cardiac Failure*, in press.

II. Oversigtsartikler & letters (39)

1. Rehfeld JF, Bardram L, Bundgaard JR, Friis-Hansen L, **Gøtze JP**, Hilsted L, Johnsen AH, Lüttichau HR, Nielsen FC, Paloheimo L, Pedersen K, Rourke IJ, van Solinge WW, Thorup JU. Expression and growth effects of gastrin and cholecystokinin peptides in neuroendocrine tumors and common carcinomas. *Falk Symposium No. 77: Gastrointestinal tract and endocrine system* (Klüwer Academic Publications, Lancaster, UK, 1995; pp. 379-405).
2. **Gøtze JP**, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. *Scand J Clin Lab Invest Suppl* 2001;234:47-51.
3. Rehfeld JF, **Gøtze JP**. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. *Curr Mol Med* 2003;3:25-38.
4. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Progastrin, gastrins and bioactivity. Proceedings of the 11th International Conference on Ulcer Research, Dubrovnik, Croatia, September 15-20, 2003.
5. Rehfeld JF, Bundgaard JR, Friis-Hansen L, **Gøtze JP**. On the tissue-specific processing of procholecystokinin in the brain and gut – a short review. *J Physiol Pharmacol* 2003;54 Suppl 4:73-79.
6. Nielsen SJ, **Gøtze JP**, Raymond IE, Grønning BA, Kirk V, Bay M, Hildebrandt PR, Aldershvile J. De natriuretiske hjertehormoner. Klinisk anvendelse ved hjertesvigt. *Ugeskr Laeger* 2004;166:248-253.
7. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Naming progastrin-derived peptides. *Regul Pept* 2004;120:177-183.
8. **Gøtze JP**. ProBNP-derived peptides in cardiac disease. *Scand J Clin Lab Invest* 2004;64:497-510.
9. **Gøtze JP**. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. *Clin Chem* 2004;50:1503-1510.
10. Friis-Hansen L, **Gøtze JP**, Kastrup J. Forgiftning med betablokkere og calciumantagonister. To kardiologiske problemer med endokrinologiske løsninger? *Ugeskr Laeger* 2004;166:3483-3487.
11. **Gøtze JP**, Rehfeld JF. Cardiac processing of natriuretic peptides in heart failure. *Clin Chem* 2004;50:2467-2468.
12. Nielsen LB, **Gøtze JP**. Letter regarding article by Bibbins-Domingo et al, "B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study". (Measurement of BNP versus proBNP in patients with coronary artery disease.) *Circulation* 2005;111:15-16.
13. Rehfeld JF, **Gøtze JP**. Gastrin vaccination against gastrointestinal and pancreatic cancer. *Scand J Gastroenterol* 2006;41:122-123.
14. **Gøtze JP**, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. *Eur Heart J* 2006;27:1648-1650.
15. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hansen TvO. The biology of cholecystokinin and gastrin peptides. *Curr Top Med Chem* 2007;7:1154-1165.

16. **Gøtze JP**, Hillarp A, Lindblom A, Björk P, Strandberg K, Nielsen LB. Ny markør ved trombotisk trombocytopenisk purpura. *Ugeskr Laeger* 2008;**170**:2446-2449.
17. **Gøtze JP**, Lindblom A, Björk P, Nielsen LB, Strandberg K, Manea M, Hillarp A. ADAMTS13 – aktör och markör vid trombotisk mikroangiopati. *Läkartidningen* 2008;**105**:1092-1095.
18. Christoffersen C, Lethagen S, **Gøtze JP**. Heparininduceret trombocytopeni. *Ugeskr Laeger* 2009;**171**:612-615.
19. Smith J, **Gøtze JP**, Andersen CB, Vejlstrup N. Practical application of natriuretic peptides in paediatric cardiology. *Cardiol Young* 2010;**20**:353-363.
20. Veien KT, Jensen JK, Hildebrandt P, **Gøtze JP**, Nielsen OW, Køber L. Natriuretiske peptider som hjertemarkører I klinisk praksis. *Ugeskr Laeger* 2010;**172**:2111-2116.
21. Lippert SK, **Gøtze JP**. C-type natriuretic-derived peptides as biomarkers in human disease. *Biomark Med* 2010;**4**:631-639.
22. **Gøtze JP**, Johnsen AH, Rehfeld JF. Letter regarding article by Siriwardena M et al.: B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. *Circulation* 2011;**123**:e232.
23. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hilsted L, Nielsen FC. Diagnostik af neuroendokrine tumorer I mave-tarm-kanalen. *Ugeskr Laeger* 2010;**172**:2957-2960.
24. Crimmins DL, **Gøtze JP**. In vitro molecular structure of N-terminal B-type natriuretic peptide: monomer or oligomer? *Clin Chem* 2011;**57**:924-926.
25. **Gøtze JP**, Hunter I, Lippert SK, Bardram L, Rehfeld JF. Processing-independent analysis of peptide hormones and prohormones in plasma. *Front Biosci (Landmark Ed.)* 2012;**17**:1804-1815.
26. **Gøtze JP**. B-type natriuretic peptide: From post-translational processing to clinical measurements. *Clin Chem* 2012;**58**:83-91.
27. Rehfeld JF, Bardram L, Hilsted, L, Poitras P, **Gøtze JP**. Pitfalls in diagnostic gastrin measurements. *Clin Chem* 2012;**58**:831-836.
28. **Gøtze JP**, Hunter I, Smith J, Hasenkam JM. Pigs in space. *Cardiovasc Endocrinol* 2013;**2**:4-5.
29. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Making sense of chromogranin A in heart disease. *Lancet Diabetes Endocrinol* 2013;**1**:7-8.
30. Bergen M, **Gøtze JP**. On the nature of depression: cardiovascular light for a shady condition. *Cardiovasc Endocrinol* 2013;**2**:38-39.
31. Van Der Vekens N, Hunter I, **Gøtze JP**, Decloedt A, De Clercq D, Van Loon G. Human and equine cardiovascular endocrinology: beware to compare. *Cardiovasc Endocrinol* 2013;**2**:67-76.
32. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as biomarker in cardiovascular disease. *Biomarkers Med* 2014;**8**:133-140.
33. Hunter I, Terzic D, Zois NE, Olsen LH, **Gøtze JP**. Pig models for the human heart failure syndrome. *Cardiovasc Endocrinol* 2014;**3**:15-18.

34. Okholm C, **Gøtze JP**, Svendsen LB, Achiam MP. Inflammatory response in laparoscopic vs. open surgery for gastric cancer. *Scand J Gastroenterol* 2014, in press.
35. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, **Gøtze JP**. Natriuretic peptides in cardiometabolic regulation and disease. *Nat Rev Cardiol* 2014;**11**:402-422.
36. Jespersen CHB, Vestergaard KR, Schou M, Teisner B, Sinosich M, **Gøtze JP**, Iversen K. Pregnancy associated plasma protein A (PAPP-A) and the vulnerable plaque. *Biomarkers Med* 2014;**8**:1033-47.
37. Guo S, Barringer F, Zois NE, **Gøtze JP**, Ashuna M. Natriuretic peptides in cerebral hemodynamics. *Regul Peptides* 2014;**192-193**:15-23.
38. Albrethsen J, **Gøtze JP**, Johnsen AH. Mining the granule proteome for endocrine markers. *Biomarkers Med*, in press.
39. **Gøtze JP**, Hansen LH, Terzic D, Zois NE, Albrethsen J, Timm A, Smith J, Soltysinska E, Lippert SK, Hunter I. Atrial natriuretic peptides in plasma. *Clin Chim Acta*, in press.

III. Editorials (11)

1. **Gøtze JP**, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: Does the endocrine heart also fail in heart failure? *Eur Heart J* 2003;**24**:1471-1472.
2. **Gøtze JP**, Videbæk R. More hormones spilt in heart failure: linking renal sympathetic activation to clinical outcome. *Eur Heart J* 2005;**26**:861-862. (10-1093/eurheartj/ehi220).
3. **Gøtze JP**. Coronary artery disease, heart failure, and cardiac natriuretic peptides in the middle. *Eur Heart J* 2005;**26**:2603-2604.
4. Christoffersen C, Hunter I, Jensen AL, **Gøtze JP**. Diabetes and the endocrine heart. *Eur Heart J* 2007;**28**:2427-2429.
5. **Gøtze JP**. Markers of activated coagulation in acute coronary syndromes. *J Am Coll Cardiol* 2008;**51**:2430-2431.
6. **Gøtze JP**, Rehfeld JF. Peptide hormones and their prohormones as biomarkers. *Biomark Med* 2009;**3**:335-338.
7. Hunter I, **Gøtze JP**. Next generation natriuretic peptide measurement. *Adv Clin Chem* 2012;**58**:45-48.
8. **Gøtze JP**. Defining cardiovascular endocrinology. *Cardiovasc Endocrinol* 2012;**1**:2-3.
9. **Gøtze JP**, Køber L. Genotype versus phenotype in cardiology: just a new coat of paint? *Biomark Med* 2013;**7**:501-503.
10. **Gøtze JP**, Krentz A. Animal models. *Cardiovasc Endocrinol* 2014;**3**:1.
11. **Gøtze JP**, Albrethsen J. Adropin: A new regulatory peptide in cardiovascular endocrinology. *Regul Pept* 2014;190-191:41-42.

IV. Bogkapitler (7)

1. Rehfeld JF, **Gøtze JP**. The post-translational phase of gene expression in tumor diagnosis. M.A. Hayat (Ed): Handbook of immunohistochemistry and *in situ* hybridization of human carcinomas (volume 4). *Elsevier Academic Press USA* 2006:23-32.
2. **Gøtze JP**. Biosynthesis of cardiac natriuretic peptides. D. Richter & H. Tiedge (Eds): Cellular Peptide Hormone Synthesis and Secretory Pathways. *Results Probl Cell Differ* 2010;**50**:97-120 (*Springer Press*).
3. Rehfeld JF, **Gøtze JP**. Gastrin. Handbook of Biologically Active Peptides (2nd edition). Kastin AJ (Ed), *Academic Press* 2013:519-523.
4. Apple FS, **Gøtze JP**, Jaffe AS. Cardiac function. Tietz textbook of clinical chemistry and molecular diagnosis (5th edition). *Elsevier Saunders* 2012:1457-1522.
5. Apple FS, **Gøtze JP**, Jaffe AS. Cardiovascular disease. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (seventh edition). *Elsevier Saunders* 2014:632-650.
6. Terzic D, **Gøtze JP**. Copeptin and the heart failure syndrome. *UNI-MED Verlag AG* 2014;62-69.
7. Rehfeld JF, **Gøtze JP**. Forskning på klinisk biokemisk afdeling, Rigshospitalet 1954-2014 (ISBN 978-87-990619-1-4).

V. Andre publikationer (15)

1. Friis-Hansen L, **Gøtze JP**, Philip J. Graviditetskomplikationer og trombofili. *Ugeskr Laeger* 1999;**161**:5034.
2. Rehfeld JF, **Gøtze JP**. Barretts metaplasi og øsofaguskræft. *Ugeskr Laeger* 2003;**165**:2498.
3. **Gøtze JP**, Friis-Hansen L, Thorsen S, Rehfeld JF. Langtidsprofylakse efter venøs tromboembolisk sygdom. *Ugeskr Laeger* 2003;**165**:2896-2897.
4. **Gøtze JP**, Rehfeld JF. Hjertereptider – basalt set. *Ugeskr Laeger* 2003;**165**:3324-3325.
5. **Gøtze JP**, Rehfeld JF. Hjertehormonologi. *Ugeskr Laeger* 2004;**166**:1109.
6. **Gøtze JP**. Hjertets egne hormoner. *Klinisk Biokemi i Norden* 2005;**17**:8-12.
7. Rehfeld JF, **Gøtze JP**. Galdesten som symptom på kolecystokininresistens. *Ugeskr Laeger* 2005;**167**:2658-2659.
8. **Gøtze JP**, Hansen SH, Johnsen AH. Tacrolimus i blod: Immunsuppresiva analyseret med LC-MS/MS. *DSKB-Nyt* 2006;**2**:26-27.
9. **Gøtze JP**, Svensson PJ. Trombosbehandlingens længde bør ikke styras af D-dimer. *Läkartidningen* 2007;**104**:851.
10. **Gøtze JP**, Nielsen LB. Heparin-induceret immunbetinget trombocytopeni. *DSTH-Forum* 2007;**2**:16-17.
11. **Gøtze JP**, Carlsson M, Friis-Hansen L, Nybo M, Thornemo M, Karlman M, Karawajczyk M, Zelvute I, Janukonyte J, Hel M, Frøyshov B, Aldrimer M. The professional role in a clinical chemistry laboratory: Snapshots from a boat trip to Bornholm. *Klinisk Biokemi i Norden* 2007;**19**:22-31.
12. Hunter I, Jensen AL, Koch J, Bjørnvad C, Smith J, **Gøtze JP**. Det endokrine hjerte og biokemisk diagnostik af hjertesygdom. *Dansk Veterinærtidsskrift* 2008;**91**:8-12.
13. Rehfeld JF, Bardram L, **Gøtze JP**, Hilsted L. Gastrin som markør af gastrinomer: Et lærestykke om immunanalyse-kits. *Klinisk Biokemi i Norden* 2011;**3**:20-24.
14. Hammarsten O, **Gøtze JP**. Copeptin: A new peptide in clinical measurement. *Klinisk Biokemi i Norden* 2012;**1**:22-31.
15. Brødbæk K, **Gøtze JP**. Fatal blødningskomplikation hos patient med akut nyresvigt behandlet med dabigatran. *DSKB Nyt* 2013;**1**:16-18.

VI. Indlæg (7)

1. **Gøtze JP.** *Ugeskr Læger* 2001;**163**:7291.
2. Siersbæk Hansen L, **Gøtze JP.** *Ældre og Sundhed* 2002;**1**:14-15.
3. **Gøtze JP.** Fra spire til sten. *DSKB Nyt* 2009;**1**:22-23.
4. **Gøtze JP.** Krudtugler på stoffer. *Information* 2013;**29**:18-19.
5. **Gøtze JP.** Pausegymnastik. *Information* 2013;**34**:16-17.
6. **Gøtze JP.** Jeppe på fedtberget. *Information* 2013;**38**:14-15.
7. **Gøtze JP.** Drømmen og det lykkelige menneske. *Berlingske Tidende* 2014;**33**:25.

VII. Patentansøgninger (2)

1. A processing-independent neuropeptide assay. Rehfeld JF, **Gøtze JP**. Offentliggjort den 11. april 2003 (WO03/087819).
2. Use of progastrin-derived peptides. Rehfeld JF, Bundgaard JR, **Gøtze JP**. Ansøgning indleveret den 6. februar 2004 (PA 2004 00180).

VIII. Manuskripter indsendt til tidsskrift

1. **Gøtze JP**, Johnsen AH, Johnbeck CB, Rehfeld JF. Cardiomyocyte expression and cell-specific processing of procholecystokinin. Submitted.
2. Kousholt B, Larsen JR, Bartels ED, Hasenkam JM, Nielsen LB, Burnett Jr JC, **Gøtze JP**. B-type natriuretic peptide increases cardiac triglyceride accumulation after myocardial infarction in pigs. Submitted.
3. Rehfeld JF, Hansen J, Sonne DP, **Gøtze JP**. Problematic commercial immunoassay kits. Submitted.
4. Timm A, Hillarp A, Philips M, **Gøtze JP**. Comparison of automated von Willebrand factor activity assays. Submitted.
5. Mygind ND, Iversen K, Køber L, **Gøtze JP**, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The prognostic significance of the inflammatory biomarker YKL-40 in relation to mortality in all-comers. A follow-up study after 11 years. Submitted.
6. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen V, Gadsbøll N. The influence of high versus low sodium intake on blood pressure and hemodynamics in patients with morbid obesity. Submitted.
7. Olsen NT, Sogaard P, Larsson HBW, **Gøtze JP**, Jøns C, Mogelvang R, Nielsen OW, Fritz-Hansen T. Prediction of progressive left ventricular dilatation and development of symptoms in asymptomatic chronic aortic regurgitation with speckle tracking echocardiography. Submitted.
8. Harutyunyan MJ, Mathiasen AB, Winkel P, **Gøtze JP**, Fisher-Hansen J, Hildebrandt PR, Jensen GB, Hilden J, Jespersen CM, Kjølner E, Kolmos HJ, Gluud C, Kastrup J. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: A prognostic study within the CLARICOR trial. Submitted.
9. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated NT-proBNP: A 10-year analysis from the Copenhagen Hospital Heart Failure Study. Submitted.
10. Nielsen SJ, Asferg CL, Andersen UB, Linneberg A, Jøns C, **Gøtze JP**, Jeppesen J. Abnormal proANP response to an oral glucose challenge in obese men. Submitted.
11. Eskesen K, Sogaard P, Larsson H, **Gøtze JP**, Fritz-Hansen T, Olsen NT. Determinants of N-terminal pro-B-type natriuretic peptide levels and correlation with outcome in chronic aortic regurgitation. Submitted.
12. Christensen HM, Kistorp C, Schou M, Keller N, Frystyk J, Flyvbjerg A, **Gøtze JP**, Faber J. Ongoing muscle wasting despite stable weight in cachectic heart failure patients: A prospective study. Submitted.
13. Van Der Vekens N, Hunter I, Timm A, Declodt A, De Clercq D, **Gøtze JP**, van Loon G. Total plasma proANP associated with atrial dilation in horses. Submitted.
14. Fabiansen C, Lykke M, Hother A, Koch J, Nielsen OB, Hunter I, **Gøtze JP**, Friis H, Thymann T. Cardiac remodeling in malnourished piglets. Submitted.
15. Cetti RH, Nielsen JE, Jørgensen A, Grønkær B, **Gøtze JP**, Jørgensen N. Cholesterol in human seminal fluid associated with semen quality. Submitted.
16. Asferg CL, Andersen UB, Linneberg A, Hedley PL, Christensen M, **Gøtze JP**, Esler M, Jeppesen J. Neuroendocrine markers associated with 24 hour ambulatory blood pressure in obese men. Submitted.
17. Skov J, Pedersen M, Holst JJ, Madsen B, **Gøtze JP**, Rittig S, Jonassen T, Frøkiær J, Dejgaard A, Christiansen JS. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: A randomized clinical trial. Submitted.
18. Ambrus RB, Achiam M, **Gøtze JP**, Fukuoma D, Secher N, Svendsen LB. Atrial natriuretic peptide during abdominal surgery. Submitted.
19. Goharian T, Gimsing AN, **Gøtze JP**, Faber J, Andersen LB, Grøntved A, Jeppesen J. Tanner stage, mid-regional proANP, and blood pressure in adolescents: Effect of gender. Submitted.
20. Von Scholten BJ, Hansen TW, **Gøtze JP**, Persson F, Rossing P. Glucagon-like peptide 1 receptor antagonist (GLP-1RA): Long-term effect on kidney function in patients with type 2 diabetes. Submitted.
21. Mylin AK, **Gøtze JP**, Heickendorff L, Abildgaard N, Gimsing P. C-type natriuretic peptide in multiple myeloma. Submitted.

22. Valeur N, Ersboll M, Sogaard P, Hassager C, **Gøtze JP**, Kober L. Chromogranin A concentrations are associated with prognosis but not left ventricular systolic function in patients with myocardial infarction. Submitted.
23. Gaborit F, Bosselman H, Tønder N, Iversen K, Kumler T, Kistorp C, Söletormos G, **Gøtze JP**, Schou M. Left ventricular global longitudinal strain associated with natriuretic peptides in outpatients with chronic systolic heart failure. Submitted.